Join Growin Stock Community!

Amneal pharmaceuticals, inc.AMRX.US Overview

US StockHealthcare
(No presentation for AMRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AMRX AI Insights

AMRX Overall Performance

AMRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AMRX Recent Performance

-2.90%

Amneal pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AMRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AMRX Key Information

AMRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AMRX Profile

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Price of AMRX

AMRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AMRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.23
PE Ratio (TTM)
1381.00
Forward PE
-
PS Ratio (TTM)
1.48
PB Ratio
86.10
Price-to-FCF
17.33
METRIC
VALUE
vs. INDUSTRY
Gross Margin
36.88%
Net Margin
2.39%
Revenue Growth (YoY)
8.05%
Profit Growth (YoY)
9.10%
3-Year Revenue Growth
10.12%
3-Year Profit Growth
11.33%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.23
PE Ratio (TTM)
1381.00
Forward PE
-
PS Ratio (TTM)
1.48
PB Ratio
86.10
Price-to-FCF
17.33
Gross Margin
36.88%
Net Margin
2.39%
Revenue Growth (YoY)
8.05%
Profit Growth (YoY)
9.10%
3-Year Revenue Growth
10.12%
3-Year Profit Growth
11.33%

  • When is AMRX's latest earnings report released?

    The most recent financial report for Amneal pharmaceuticals, inc. (AMRX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AMRX's short-term business performance and financial health. For the latest updates on AMRX's earnings releases, visit this page regularly.

  • Where does AMRX fall in the P/E River chart?

    According to historical valuation range analysis, Amneal pharmaceuticals, inc. (AMRX)'s current price-to-earnings (P/E) ratio is 60.3, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of AMRX?

    According to the latest financial report, Amneal pharmaceuticals, inc. (AMRX) reported an Operating Profit of 112.03M with an Operating Margin of 13.76% this period, representing a growth of 47.81% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AMRX's revenue growth?

    In the latest financial report, Amneal pharmaceuticals, inc. (AMRX) announced revenue of 814.32M, with a Year-Over-Year growth rate of 11.47%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AMRX have?

    As of the end of the reporting period, Amneal pharmaceuticals, inc. (AMRX) had total debt of 2.69B, with a debt ratio of 0.73. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AMRX have?

    At the end of the period, Amneal pharmaceuticals, inc. (AMRX) held Total Cash and Cash Equivalents of 310.87M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AMRX go with three margins increasing?

    In the latest report, Amneal pharmaceuticals, inc. (AMRX) achieved the “three margins increasing” benchmark, with a gross margin of 36.5%%, operating margin of 13.76%%, and net margin of 4.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AMRX's profit trajectory and future growth potential.

  • Is AMRX's EPS continuing to grow?

    According to the past four quarterly reports, Amneal pharmaceuticals, inc. (AMRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AMRX?

    Amneal pharmaceuticals, inc. (AMRX)'s Free Cash Flow (FCF) for the period is 87.86M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 8.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AMRX?

    The latest valuation data shows Amneal pharmaceuticals, inc. (AMRX) has a Price-To-Earnings (PE) ratio of 60.3 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.